Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Insmed Inc

INSM ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$126.68

▲ +0.04%

Market Cap $27.66B · Vol 508.34K

Key Metrics

P/E Ratio

N/A

FWD: 1,296.43

Market Cap

$27.66B

Large Cap

Div Yield

N/A

EPS Growth

+76.05%

YoY

RSI (14)

54.87

Momentum

Beta

0.81

vs Market

52W High

$212.59

40.43% below

52W Low

$90.41

40.06% above

Volume

508.34K

Avg 850.88K

P/B

50.46

Price-to-book

ROE

-249.28%

Return on equity

Free Float

99.46%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Insmed Inc (INSM) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INSM pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.36%

+28.67%

+21.97%

-13.82%

YTD

-27.21%

-11.72%

+459.54%

+344.34%

Financials & Valuation

TTM · Annual

Total Revenue	$606.42M
Net Income	$-1,276,775,000.00
Revenue Growth (YoY)	+296.11%
Gross Margin	78.74%
Operating Margin	-164.04%
Net Profit Margin	-210.54%
ROE	-249.28%
ROA · ROIC	-59.29% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	1,296.43
PEG Ratio	N/A
P/S	57.12
P/B	50.46
P/FCF	N/A
EPS Growth	+76.05%
Outstanding Shares	218.38M

Technical Indicators

50-Day SMA	$115.26
200-Day SMA	$141.17
RSI (14)	54.87
Beta	0.81
52-Week High	$212.59
52-Week Low	$90.41

Volume Today	508.34K
Avg Daily Volume (30D)	850.88K
Relative Volume	0.60x
Volatility (10D)	31.03
Volatility (30D)	89.86
Free Float	99.46%

Analyst Consensus

BUY

Current Price $126.68

Mean Target $201.15

52W Low$90.41 52W High$212.59

Current

Target

$90.41 $212.59

Current Analyst target

+58.78% upside potential · 23 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S9SKW7

ISINUS4576693075

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.77% ARGX.BR argenx SE +1.31% ARGX argenx SE -0.18% 2269.HK WuXi Biologics (Cayman) Inc +2.97% GMAB Genmab A/S +0.57%

Company Profile

Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.